Prognostic factors for survival in patients with metastatic melanoma treated with ipilimumab: Turkish Oncology Group (TOG) Study


Urun Y., Abali H., Turna H., Esin E., Sedef A. M. , Alkan A., ...Daha Fazla

European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51 identifier